A recent study from the University of Georgia found that no rural counties had a PET scan facility, which is used to diagnose ...

Significant adverse events — such as ARIA — with lecanemab, the drug that slows Alzheimer's, is rare and manageable, ...

Sen. Bill Cassidy (R-LA) argued in an interview released Wednesday that drug companies must be allowed to make a profit to ...

Patients in the earliest stage of Alzheimer disease, with very mild symptoms, experienced the lowest risk of complications ...

Rural Georgians may find it difficult to access medication that could slow the progression of Alzheimer's disease, according ...

New data show that lecanemab is well tolerated outside of clinical trial setting, with expected and manageable side effects.

In 2023, the Food and Drug Administration (FDA) approved lecanemab, a new therapy for Alzheimer’s disease. This approval ...

Adoption of lecanemab, a novel infusion treatment for Alzheimer’s disease (AD), has been disproportionately higher among ...

Access to a new Alzheimer’s treatment, lecanemab, shows major disparities tied to race, gender, and income. Disparities in ...

Viehbacher, “Biogen”) announced today that the European Commission (EC) has granted the amyloid-beta (Aβ) monoclonal antibody Leqembi ® (lecanemab) Marketing Authorization (MA) in the ...

Treatment with lecanemab infusion was safe and generally well-tolerated within an outpatient memory clinic setting, with few infusion-related reactions and a low number of withdrawals due to adverse ...

Photograph by SIMON FRASER/MRC UNIT, NEWCASTLE GENERAL HOSPITAL/SCIENCE PHOTO LIBRARY The drug the FDA approved last week, known as lecanemab, is the first to show evidence of slowing cognitive ...